Business Wire

REPLY

28.4.2022 14:02:13 CEST | Business Wire | Press release

Share
REPLY: Area42, the Development Centre Dedicated to the Most Innovative Technologies in the Robotics, Advanced Mobility and Virtual Reality Sectors, Opens Its Doors

Today Reply inaugurates Area42 , the new applied research centre focused on developing the most innovative technologies. The Area42 “corner Labs” are driven by cutting-edge work in the areas of Autonomous Warehouse, Last Mile Delivery, Robotics, Connected Products, Blockchain and the Metaverse . Reply’s experts are working on these technologies on a daily basis, transforming ideas into innovative prototypes, exploiting their full potential and applying them to real use industrial cases.

The Area42 Laboratories are the distinctive component of Reply’s new Turin headquarters, which covers an area of over 20,000 square metres. Each workspace has been completely renovated and optimised in line with the Group’s new working models, which focus on a more open and collaborative approach. Reply will host its customers in the new spaces, collaborating with them to experiment, incubate new concepts, and test the latest technologies in a way that enables digital products and services to be adapted to their specific innovation context.

The 6 Area42 Laboratories focus on the key themes representing the most advanced frontiers of innovation for the industrial world:

- Autonomous Warehouse, the Area42 laboratory where solutions are studied and developed for the autonomous management of warehouse activities, thanks to the use of autonomous drones and vehicles capable of interfacing with innovative warehouse management platforms such as LEA Reply;

- Last mile delivery , the Area42 laboratory focused on the mobility of self-driving vehicles and robots within pre-defined spaces (e.g., campuses, hospitals, factories, etc.) that are capable of interacting with the surrounding environment;

- Robotics , the Area42 laboratory that combines Artificial Intelligence technologies with robotics to study the agility of autonomous robots and use scenarios focused on the interaction between the latter and large environments requiring repetitive maintenance and control activities;

- Connected Products, the Area42 space focused on the design and development of connected products and services, from the prototyping of devices to the creation of front-end applications, also thanks to the support of IoT accelerators;

- Blockchain , in the context of an ever-greater evolution of the concepts of smart cities and shared mobility, this Area42 laboratory experiments with the application of blockchain technologies for enabling real scenarios based on the Digital Identity of Vehicles;

- Metaverse, the Area42 laboratory focused on the application and integration of Mixed Reality solutions to create immersive applications in virtual environments, where users can enter and move around and where virtual and physical objects co-exist.

“The Area42 laboratories represent a unicum in the modern technological panorama,” affirmed Filippo Rizzante, Reply CTO. “Here, we give life to new and innovative concepts and apply the latest technologies to provide solutions capable of creating value for business and for society as a whole. We experiment with and implement innovative ideas that have a strategic impact and generate a competitive advantage for our customers. Currently, our focus is on six highly topical issues, but technological evolution will always continue to drive us further, in line with what has always been our approach at Reply: to prepare for and make the future a tangible reality”.

Area42 joins Reply’s existing laboratories in Europe: the Test Automation Centre , focused on the automated monitoring and testing of the quality of business-critical products and services; the IoT Validation Lab , where interconnected solutions are validated and also integrated with Reply’s new Turin headquarters, creating the most advanced hub of laboratories for the industry sector; Area 360, the centre for augmented and virtual reality based in Milan which was created to support businesses; the Immersive Experience Lab in Munich, which experiments with next-generation immersive experiences; the Cyber Security Lab , in Cologne, focused on the study and testing of cyber threats; and finally, Reply’s new labs opening soon in London which will be dedicated to robotics, edge computing and sensory technologies.

“The creation of Area42 is part of a broader project of excellence in terms of property redevelopment that we have initiated here in Turin”, continues Tatiana Rizzante. “While carefully respecting the constraints imposed by the Superintendency of Architectural Heritage in relation to what is certainly considered a symbol of modern architecture, we wanted to create harmonious and stimulating spaces to work, exchange ideas and carry out research. The interconnection of spaces created to accommodate different functions – from individual to team work, from the sharing of projects to leisure time, from lounges to the most advanced laboratories – creates a fluid and open space. Our team of experts, but also our customers and partners, can thus take advantage of a truly immersive experience and experiment with technological innovation”.

The Lingotto building that hosts Area42, located in Via Nizza no. 250 in Turin and recently acquired by the Group, has been the subject of a major renovation project which, together with works currently under way at the former Caserma de Sonnaz, make it possible to revive and reinterpret – with a contemporary touch – two iconic buildings for the city of Turin.

The projects are driven by the concepts of innovation, collaboration and well-being, placing the focus on the two main protagonists: people and research.

The completely renovated Lingotto building offers open spaces and new paths, created to facilitate business relationships and enlivened by the most current languages and codes. Reply’s people find themselves immersed in a large, multi-functional space with areas off limits to mobile phones and meetings to facilitate concentration. Common areas are dedicated not only to brainstorming, but also to sports, catering and leisure, for a more effective sharing of ideas and socialisation in the workplace: an active and ever-evolving ecosystem.

Reply

Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye